Chemistry:Surufatinib
From HandWiki
Surufatinib (trade name Sulanda) is pharmaceutical drug for the treatment of cancer. In China, it is approved for late-stage, well-differentiated, extrapancreatic neuroendocrine tumors.[1]
It is also under investigation for the treatment of other types of solid tumors.[2][3]
Surufatinib targets fibroblast growth factor receptor 1 (FGFR1).[4]
References
- ↑ "Surufatinib: First Approval". Drugs 81 (6): 727–732. April 2021. doi:10.1007/s40265-021-01489-y. PMID 33788183.
- ↑ "Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment". Frontiers in Oncology 13. 2023. doi:10.3389/fonc.2023.1158857. PMID 37361567.
- ↑ "First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors". Journal of Clinical Oncology 32 (15_suppl): 2615. 2014. doi:10.1200/jco.2014.32.15_suppl.2615.
- ↑ "Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R". Communications Chemistry 7 (1). January 2024. doi:10.1038/s42004-023-01084-0. PMID 38172256. Bibcode: 2024CmChe...7....3L.
 |  |
